Scholarlink

<p>Excessive osteoclast activation disrupts bone homeostasis, contributing to osteoporosis (OP). While Runx2 is known to regulate osteoblast differentiation, its role in osteoclasts is less clear. Using conditional knockout models, we demonstrate that Runx2 directly drives osteoclast differentiation by regulating <i>Ctsk</i> transcription. However, its dual function in both osteoblasts and osteoclasts limits therapeutic potential. We identify Ip6k2 as a Runx2-interacting protein that enhances Runx2-dependent <i>Ctsk</i> transcription specifically in osteoclasts. Genetic deletion of <i>Ip6k2</i> phenocopies <i>Runx2</i> loss in osteoclasts, suppressing osteoclastogenesis and increasing bone mass without affecting osteoblast function. Notably, dual deletion of <i>Runx2</i> and <i>Ip6k2</i> yields no additive effects, indicating a shared regulatory pathway. Importantly, both genetic and pharmacological inhibition of Ip6k2 protect against estrogen deficiency- and age-induced bone loss. Collectively, our findings position Ip6k2 as a promising osteoclast-specific target and highlight that disruption of the Ip6k2-Runx2 complex may offer an effective strategy for OP treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting the Ip6k2–Runx2 axis disrupts osteoblast–osteoclast coupling to treat osteoporosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月30日

查看全文
  • Guixing Ma,
  • Yong Chen,
  • Siyuan Cheng,
  • Fen Wang,
  • Yingying Han,
  • Litong Chen,
  • Zhen Ding,
  • Yiran Li,
  • Huiling Cao

摘要

Excessive osteoclast activation disrupts bone homeostasis, contributing to osteoporosis (OP). While Runx2 is known to regulate osteoblast differentiation, its role in osteoclasts is less clear. Using conditional knockout models, we demonstrate that Runx2 directly drives osteoclast differentiation by regulating Ctsk transcription. However, its dual function in both osteoblasts and osteoclasts limits therapeutic potential. We identify Ip6k2 as a Runx2-interacting protein that enhances Runx2-dependent Ctsk transcription specifically in osteoclasts. Genetic deletion of Ip6k2 phenocopies Runx2 loss in osteoclasts, suppressing osteoclastogenesis and increasing bone mass without affecting osteoblast function. Notably, dual deletion of Runx2 and Ip6k2 yields no additive effects, indicating a shared regulatory pathway. Importantly, both genetic and pharmacological inhibition of Ip6k2 protect against estrogen deficiency- and age-induced bone loss. Collectively, our findings position Ip6k2 as a promising osteoclast-specific target and highlight that disruption of the Ip6k2-Runx2 complex may offer an effective strategy for OP treatment.